Last updated: 2026-10-13 21:31:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Citius Pharmaceuticals Inc. (CTXR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.47, with a market capitalisation of $13.71M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.46 to $2.19. This page covers its latest market performance, valuation, price trends and company information.
$13.71M | |
$0.48 | |
$137.25 | |
$0.46 | |
$0.49 | |
191.71K | |
532.66K | |
-- | |
$2.19 | |
$0.46 | |
-- | |
-- |
Citius Pharmaceuticals Inc. (CTXR) is trading at $0.48 in after-hours trading as of 2026-10-13 20:58:00, down 3.61% ($0.02) from the regular-session close of $0.49.
After-hours trading shows how investors are pricing CTXR after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Citius Pharmaceuticals Inc. (CTXR) moved from $0.53 to $0.47, representing a decline of 11.21% ($0.06).
The stock traded between $0.46 and $0.55 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 170.25 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.5%
CTXR is currently trading at $0.47, placing it 0.5% of the way from its 52-week low of $0.46 to its 52-week high of $2.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Citius Pharmaceuticals Inc. (CTXR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.